| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
156,079 |
229,843 |
273,203 |
611,547 |
| Total Sell Value |
$13,472,349 |
$20,340,408 |
$24,241,430 |
$58,103,504 |
| Total People Sold |
5 |
5 |
6 |
7 |
| Total Sell Transactions |
13 |
19 |
25 |
55 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wood Mark |
VP, Human Resources |
• – – |
2009-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
6,650 |
|
- |
|
| Davis George Eric |
VP, General Counsel |
• – – |
2009-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
17,203 |
|
- |
|
| Grey Michael G |
Director |
– • – |
2009-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
8,750 |
|
- |
|
| Klein Joseph III |
Director |
– • – |
2009-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
45,000 |
|
- |
|
| Aselage Steve |
SVP, Global Commercial Dev |
• – – |
2009-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
45,916 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2009-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
32,000 |
45,440 |
|
- |
|
| Cooper Jeffrey H |
SVP, Chief Financial Officer |
• – – |
2009-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
14,502 |
|
- |
|
| Lewis Alan |
Director |
– • – |
2009-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
15,000 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2009-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
49,187 |
|
- |
|
| Davis George Eric |
VP, General Counsel |
• – – |
2009-04-30 |
4 |
A |
$10.93 |
$16,648 |
D/D |
1,523 |
9,703 |
|
- |
|
| Aselage Steve |
SVP, Global Commercial Dev |
• – – |
2009-04-30 |
4 |
A |
$10.93 |
$16,560 |
D/D |
1,515 |
33,916 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2009-04-30 |
4 |
A |
$10.93 |
$16,648 |
D/D |
1,523 |
13,440 |
|
- |
|
| Cooper Jeffrey H |
SVP, Chief Financial Officer |
• – – |
2009-04-30 |
4 |
A |
$10.93 |
$15,916 |
D/D |
1,456 |
6,502 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2009-04-30 |
4 |
A |
$10.93 |
$16,659 |
D/D |
1,524 |
40,187 |
|
- |
|
| Meier Richard A |
Director |
– • – |
2009-03-13 |
4 |
B |
$11.45 |
$11,450 |
D/D |
1,000 |
4,250 |
2.39 |
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• – – |
2009-03-05 |
4 |
A |
$10.04 |
$10,039 |
D/D |
1,000 |
11,917 |
|
- |
|
| Klein Joseph III |
Director |
– • – |
2009-03-05 |
4 |
B |
$10.07 |
$50,363 |
D/D |
5,000 |
42,500 |
2.39 |
- |
|
| Bienaime Jean Jacques |
Director |
– • – |
2009-03-05 |
4/A |
B |
$10.04 |
$10,039 |
D/D |
1,000 |
11,917 |
2.39 |
- |
|
| Meier Richard A |
Director |
– • – |
2009-03-03 |
4 |
B |
$10.75 |
$10,750 |
D/D |
1,000 |
3,250 |
2.39 |
- |
|
| Klein Joseph III |
Director |
– • – |
2009-03-03 |
4 |
B |
$10.56 |
$52,818 |
D/D |
5,000 |
37,500 |
2.39 |
- |
|
| Meier Richard A |
Director |
– • – |
2009-03-02 |
4 |
B |
$11.10 |
$11,100 |
D/D |
1,000 |
2,250 |
2.39 |
- |
|
| Kakkis Emil D |
Chief Medical Officer |
• – – |
2009-03-02 |
4 |
AS |
$11.70 |
$92,396 |
D/D |
(7,897) |
39,621 |
|
- |
|
| Kakkis Emil D |
Chief Medical Officer |
• – – |
2009-03-02 |
4 |
OE |
$6.43 |
$50,778 |
D/D |
7,897 |
47,518 |
|
- |
|
| Fuchs Henry J |
Chief Medical Officer |
• – – |
2009-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
| Klein Joseph III |
Director |
– • – |
2009-02-24 |
4 |
B |
$12.08 |
$120,784 |
D/D |
10,000 |
32,500 |
2.39 |
- |
|
1303 Records found
|
|
Page 38 of 53 |
|
|
1.44 (1.6%) 
